Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Conditions:Colorectal Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:October 2014
End Date:July 2, 2018

Use our guide to learn which trials are right for you!

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma

The primary goal of this Phase 1 study is to characterize the safety and tolerability of
MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to
patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the
anti-tumor activity of MGD007 will also be assessed.

This is an open-label, multi-center, Phase 1 dose-escalation study to define a MTD, describe
preliminarily safety, and to assess PK, immunogenicity, and potential anti-tumor activity of
MGD007 in patients with relapsed or refractory metastatic colorectal cancer.

In the initial phase of the study, two dose schedules will be assessed in dose escalation,
once weekly and once every three weeks administration of single agent MGD007. Following the
establishment of an MTD, additional patients will enroll in four separate dose expansion
cohorts to further optimize the dose and schedule of MGD007 administration.

In all segments of the study, patients who benefit from MGD007 treatment and continue to meet
eligibility may continue treatment in Cycles 2 and beyond.

Inclusion Criteria:

- For the dose escalation cohorts, histologically-proven metastatic colorectal
adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard
treatment was declined.

- For the dose expansion cohorts, histologically-proven metastatic colorectal
adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard
therapy was declined.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Life expectancy of at least 12 weeks

- Measurable disease

- Intolerance to at least 2 prior standard therapy regimens

- Acceptable laboratory parameters

- Adult (≥18 years old)

Exclusion Criteria:

- Known brain metastasis

- Any prior history of or suspected current autoimmune disorders (with the exception of
vitiligo, resolved childhood atopic dermatitis, prior Grave's disease)

- Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation

- Prior treatment with checkpoint inhibitors and other immunotherapy treatments,
including anti-LAG-3, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies, if less than 5
half lives before study drug administration

- Prior history of Grade 3 or greater drug-related diarrhea/colitis during treatment
with checkpoint inhibitors or other immunotherapy treatments.

- Treatment with any local or systemic anti-neoplastic therapy or any other
investigational agent in the 4 weeks prior to study drug administration

- Require, at the time of study entry, treatment with steroids > 10 mg/day of oral
prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or
ophthalmic solution

- History of clinically significant cardiovascular disease, gastrointestinal disorder,
or significant pulmonary compromise.

- Second primary malignancy that has not been in remission for greater than 3 years,
with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous
intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score <6), or
resected melanoma in situ.
We found this trial at
185 Cambridge Street
Boston, Massachusetts 02114
Principal Investigator: David P Ryan, MD
Phone: 617-724-4000
Boston, MA
Click here to add this to my saved trials
9801 W. Kincey Ave
Huntersville, North Carolina 28078
Principal Investigator: John Powderly, MD
Huntersville, NC
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Todd Crocenzi, MD
Phone: 503-215-2855
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Portland, OR
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
Principal Investigator: Richard Kim, MD
Phone: 813-745-2146
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Tampa, FL
Click here to add this to my saved trials
Baltimore, Maryland 21231
Principal Investigator: Daniel Laheru, MD
Phone: 443-287-4961
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Principal Investigator: David P Ryan, MD
Phone: 617-632-5575
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Boston, MA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Principal Investigator: Herbert Hurwitz, MD
Phone: 919-668-1861
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Durham, NC
Click here to add this to my saved trials
New Haven, Connecticut 06520
New Haven, CT
Click here to add this to my saved trials